The data shows the startups that are expected to play a leading role in the life science industry in the U.S. in 2018, according to BioSpace's "NextGen Bio Class of 2018". Massachusetts-based BlueRock Therapeutics, founded in 2016, reached the highest score and is expected to be one of the United States life science startups with the biggest impact during 2018.
BlueRock Therapeutics (2016, Massachusetts) | 37 |
Prelude Fertility (2016, Georgia) | 29 |
Relay Therapeutics (2016, Massachusetts) | 16 |
Freenome (2016, California) | 15 |
Cirius Therapeutics (2016, California) | 12 |
Boragen (2017, North Carolina) | 11 |
Hyalex Orthopaedics (2017, Massachusetts) | 11 |
CBT Pharmaceuticals (2016, California) | 9 |
Corbin Therapeutics (2016, Canada) | 9 |
Tango Therapeutics (2017, Massachusetts) | 8 |
Shepherd Therapeutics (2016, Massachusetts) | 8 |
CARMA Therapeutics (2016, Pennsylvania) | 6 |
Jecure Therapeutics (2017, California) | 5 |
Indalo Therapeutics (2017, Missouri) | 5 |
Fortis Therapeutics (2016, California) | 4 |
Surrozen (2016, California) | 4 |
Immune-Onc (2016, California) | 3 |
Fibrocor Therapeutics (2017, Canada) | 3 |
Apostle (2017, California) | 1 |
DMD Therapeutics (2015, Washington) | 1 |